In patients for whom sodium intake is of medical concern (e.g. patients with congestive heart failure, renal failure, nephrotic syndrome), the sodium content of this product should be taken into account (see section 2). Polska Apteka Internetowa UK z główną siedzibą w Londynie serdecznie zaprasza do korzystania z szerokiej oferty. away from children. If this drug is taken by accident, call a doctor or poison control center right away.

Many drugs are excreted in human milk. However, it is not known whether Essentiale Forte is excreted in human milk. Due to the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue nursing or whether to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use It is not known whether Essentiale Forte® (amphotericin b) is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in breast-fed infants from Essentiale Forte® (amphotericin b) , a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Essentiale Forte should be administered by intravenous infusion, using a controlled infusion device, over a period of approximately 120 minutes. In general, the adverse events most commonly reported with Essentiale Forte® (amphotericin b) were transient chills and/or fever during infusion of the drug. Należy powiedzieć lekarzowi lub farmaceucie o wszystkich lekach stosowanych przez pacjenta obecnie lub ostatnio, a także o lekach które pacjent planuje stosować.Anaphylaxis has been reported with amphotericin B desoxycholate and other amphotericin B-containing drugs. Anaphylaxis has been reported with Essentiale Forte® (amphotericin b) with an incidence rate of < 0.1%. If severe respiratory distress occurs, the infusion should be immediately discontinued. The patient should not receive further infusions of Essentiale Forte® (amphotericin b). PRECAUTIONS General Patients were not administered premedications to prevent infusion related reactions prior to the Day 1 study drug infusion. Dosing and rate of infusion should be individualized to the needs of the specific patient to ensure maximum efficacy while minimizing systemic toxicities or adverse events.

Day 1 body temperature increased above the temperature taken within 1 hour prior to infusion (preinfusion temperature) or above the lowest infusion value (no preinfusion temperature recorded). The assay used to measure amphotericin B in the serum after administration of Essentiale Forte does not distinguish amphotericin B that is complexed with the phospholipids of Essentiale Forte from amphotericin B that is uncomplexed. The pharmacokinetic profile of amphotericin B after administration of Essentiale Forte is based upon total serum concentrations of amphotericin B. The pharmacokinetic profile of amphotericin B was determined in febrile neutropenic cancer and bone marrow transplant patients who received 1-2 hour infusions of 1 to 5 mg/kg/day Essentiale Forte for 3 to 20 days. If you are taking or have recently taken any other medicines, including medicines obtained without a prescription, talk to your doctor or pharmacist. The metabolic pathways of amphotericin B after administration of Essentiale Forte are not known. ExcretionIn empirical therapy study 97-0-034, a greater proportion of patients in the amphotericin B lipid complex group discontinued the study drug due to an adverse event than in the Essentiale Forte groups. Less Common Adverse Events